Preserving Muscle Mass During GLP-1 Weight Loss: A New Study Protocol

The advent of semaglutide and tirzepatide, powerful GLP-1 receptor agonists, has revolutionized treatment for obesity and type 2 diabetes, leading to substantial weight reduction. However, a significant concern with rapid weight loss is the concurrent loss of lean body mass (muscle), which can negatively impact metabolic health, strength, and long-term outcomes. This protocol outlines a randomized controlled trial designed to investigate if combining resistance exercise and protein supplementation can effectively mitigate lean mass loss during GLP-1 therapy.

As this document describes a study protocol, no results have been generated yet. The LEAN-PREP study is meticulously designed to measure several key outcomes to determine the efficacy of the planned interventions. The primary outcome will be the change in lean body mass, which will be precisely assessed using advanced body composition analysis techniques over the study duration. Researchers also plan to rigorously evaluate changes in fat mass, overall body weight, and crucial metabolic markers such as glucose homeostasis and insulin sensitivity. Secondary outcomes will include objective assessments of muscle strength and physical function, aiming to quantify any improvements or preservation. > The study's primary objective is to determine if a structured resistance exercise program combined with protein supplementation can significantly mitigate the loss of lean mass in individuals undergoing weight loss therapy with semaglutide or tirzepatide, aiming for a measurable difference in body composition outcomes.